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Introduction  
Adherence to clotting-factor treatment regimens, especially among adolescents and young adults 
(AYAs), is under-researched.   
 
Aim  
We determined factors associated with better adherence to prophylaxis. 
 
Methods  
From April through December 2012, a convenience sample of AYA (aged 13-25 years) persons with 
haemophilia (PWH) or von Willebrand disease (VWD) completed an online survey that assessed 
adherence to prescribed prophylactic treatment regimens (VERITAS-Pro).  Logistic regression analysis 
assessed demographic and clinical factors related to non-adherence (VERITAS-Pro≥57).   
 
Results  
Seventy-three prophylactically-treating AYAs participated.  Of which, 88%, 8%, and 4% had 
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developed an inhibitor.  Most were aged 13-17 years (56%), white (78%), non-Hispanic (88%), never 
married (94%) and had some type of health insurance (96%).   
 
Median VERITAS-Pro score was 48 (range=25─78) and 22 (30%) participants were non-adherent to 
prophylaxis (VERITAS-Pro≥57).  Final logistic regression modeling suggested that, compared to those 
aged 13-17 years, participants aged 18-25 years were 6.2 (95%CI: 1.8─21.0; p<.01) times more likely 
to be non-adherent.  Compared to respondents whose mother had at least a Bachelor’s degree, 




Results suggest that adherence efforts should be especially targeted to young adults as they transition 
from adolescence (i.e., parental supervision) and assume primary responsibility for their bleeding 
disorder care.  Healthcare providers should be mindful of AYAs whose mothers have less formal 
education and ensure that adequate time and resources are dedicated to family adherence education.  
 
Key Words  adherence, prophylaxis/prophylactic, adolescents, young adult, predictors 
Introduction  
Research over the past 50 years has demonstrated that using prophylactic treatment regimens 
in children with haemophilia can prevent repeated bleeding into the joints; subsequently reducing 
hospitalization, chronic pain, and disability—ultimately resulting in improved quality of life (QoL) [1-4]. 
Prophylaxis in children with severe haemophilia is a grade 1A recommendation based on strong 
evidence from both randomized controlled trials (RCTs) and observational research [5].  There is less 
consensus, however, about whether prophylaxis is ideal for adolescent and adult persons with 
haemophilia (PWH) [6-8].  The clinical advantages of continuing prophylaxis into adulthood have to be 
weighed against more pragmatic considerations like more frequent infusions and greater medical 
expense [7].  There is, however, a growing body of evidence suggesting that continuing prophylaxis, or 
starting secondary prophylaxis, in AYA PWH reduces the risk of bleeding and helps decrease chronic 
pain and preserve joint health and quality of life [3, 8-11]. 
Despite evidence demonstrating the benefits of prophylaxis, most data suggest that less than 
50% of patients actually follow their prescribed treatment regimens in the United States [12-15].  Many 
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and the importance of treatment, disease severity and the frequency of haemophilia symptoms, treatment 
satisfaction, frequency of administration, the amount of time spent in an HTC, reminder telephone calls, the 
age of the PWH, and the quality of relationships among patients and their health care professionals [13, 16-
20].     Previous studies, however, have not used standardized definitions of adherence, which makes 
contextualizing and comparing results difficult [12, 13, 17, 21], and adherence among AYA PWH 
remains particularly under-researched.  Exploring adherence among AYA PWH may be especially 
important given that adolescence and young adulthood represents an inflection point, where PWH start 
to take more responsibility for the management of their own disease and develop treatment habits that 
can carry over into adult life [13].  This survey determined factors associated with better adherence to 
prescribed prophylactic regimens among AYAs with a bleeding disorder using a standardized and 
validated tool. 
 
Materials and Methods  
Study Population and Recruitment 
Data describing AYA PWH’s adherence to prescribed treatment regimens and level of chronic 
pain were obtained as part of the larger Interrelationship between Management of Pain, Adherence to 
Clotting-factor Treatment, and Quality of Life (IMPACT QoL) study, which has been previously 
described [3].  Data were collected via a one-time, cross-sectional, online survey from a convenience 
sample of AYA patients with a bleeding disorder.  To be eligible to complete the survey, participants 
had to i) be aged 13-25 years, ii) read, write, and speak English, and iii) have Haemophilia A, 
Haemophilia B, or VWD.  Recruitment occurred at major US haemophilia meetings (e.g., Inhibitor 
Summits and national and state heamophilia society meetings), US haemophilia treatment centers 
(HTC), and through a Facebook™ (Facebook, Menlo Park, CA, USA) page dedicated to the study from 
April through December of 2012.  All surveys were completed electronically using SurveyMonkey™ 
(SurveyMonkey, Palo Alto, CA, USA) and Apple iPads™ (Apple, Cupertino, CA, USA).  The study was 
approved by the Munson Medical Center (Traverse City, MI, USA) institutional review board prior to 
data collection.  All data were de-identified prior to analysis [3].   
The current study uses a patient subset of the IMPACT QoL survey data to determine factors 
associated with better adherence to prophylactic clotting-factor treatment regimens among AYA (aged 
13-25 years) PWH or von Willebrand disease (VWD).  Patients who treated with on-demand regimens 
were excluded from this analysis because of small sample size and to minimize heterogeneity in the 
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a validated cut-off of adherence vs non-adherence using the VERITAS-PRN for on-demand patients 
has not been established [22].       
 
Measurement 
Prophylactic adherence was assessed using the Validated Haemophilia Regimen Treatment 
Adherence Scale (VERITAS)-Pro [23].  Possible subscale scores range from four points (most 
adherent) to 20 (least adherent), and possible total scores ranged from 24 (most adherent) to 120 (least 
adherent) [23].  Scores were calculated for the overall VERITAS-Pro and for each of the six VERITAS-
Pro subscales (Time, Dose, Plan, Remember, Skip, and Communicate) which are designed to capture 
the diverse dimensions of adherence [23].  The cutoff for non-adherent prophylactic patients was a total 
VERITAS-Pro score ≥57 as established  previously [23].  VERITAS-Pro scores were self-reported.  
Other self-reported data collected including information about participant age, gender, race, ethnicity, 
health insurance status/type, and the educational level of the participants’ parents.  Data were also 
collected about bleeding disorder type (Haemophilia A or B, or VWD), whether or not the participant 
ever developed an inhibitor to treatment, and bleeding disorder severity.  For Haemophilia A and B, 
severity was classified as mild, moderate, or severe corresponding to 6%-50%, 1-5%, and <1%, 
respectively, of the normal amount of clotting factor VIII/IX.  VWD was classified as mild, moderate, or 
severe corresponding to Type I (lower than normal levels of von Willebrand factor), Type II (lower than 
normal levels and improper functioning of von Willebrand factor), and Type III disease (absence of von 
Willebrand factor in the blood). 
 
Statistical Analysis 
Descriptive statistics and univariate relationships were assessed by tabulating adherence status 
(adherent vs non-adherent) by patient sociodemographic and clinical characteristics.  Percentages 
were used to describe categorical variables and statistical association was assessed using Fisher’s 
exact test because of small sample size.  Multivariable, parsimonious logistic regression models were 
constructed to predict prophylactic clotting-factor non-adherence (vs adherence).  Factors assessed for 
their relationship with being adherent included:  age, gender, race/ethnicity, parent’s education level, 
bleeding disorder type and severity, and history of inhibitor development.  Due to the large number of 
variables collected as part of the survey and because of the small sample size inherent in rare disease 
research, in addition to the fully adjusted models, final parsimonious models were constructed.  In the 
final parsimonious models, we decided, a priori, to include covariates in the model only if they i) were 
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statistically significant model parameter by at least 10-15% (i.e., confounded) [24], or iii) improved the 
precision of another statistically significant parameter already in the model.  All statistical analyses were 
performed using SAS 9.4 (Cary, NC) and Stata 12 (College Station, TX).  All p-values were calculated 
using two-sided tests. 
 
Results  
Overall, 108 persons aged 13-25 years with haemophilia or VWD participated in the IMPACT 
QoL study.  Thirty-five (32%) participants who reported treating on-demand (i.e., episodically) were 
excluded from the analysis.  The vast majority (95%) of AYAs who self-reported treating their bleeds 
prophylactically reported that they ‘use factor regularly or on a set schedule for prevention’ compared to 
only 5% who reported that they ‘use factor before physical activity for prevention.’  Of the 73 
prophylactically-treating AYAs remaining, 88%, 8%, and 4% had haemophilia A, B, and VWD, 
respectively.  Almost all (90%) had severe disease and 58% had never developed an inhibitor.  Most 
were aged 13-17 years (56%), white (78%), non-Hispanic (88%), never married (94%) and had some 
type of health insurance (96%) (Table 1).  Although nearly all respondents were insured, insurance type 
differed significantly by several factors.  Adolescents (vs young adults) (61% vs 34%, p=.03), whites (vs 
non-whites) (58% vs 19%, p=.01), and respondents whose mothers and had at least a bachelor’s 
degree (vs less than bachelor’s) (68% vs 32%, p=.03) were significantly more likely to have 
private/commercial insurance only (vs public/government insurance, a combination of private and public 
insurance, or no health insurance.  Among respondents, 34% had a mother who completed at least a 
bachelor’s degree and 36% had a father that did so.  The education status of the respondents’ parents 
was closely related (p<.01), and data showed that if a respondent’s mother had less than a Bachelor’s 
degree, 85% of the time so too did the father.  Likewise, if a respondent’s mother had at least a 
Bachelor’s degree, 76% of the time the father did as well.        
Median VERITAS-Pro score was 48 (range=25─78) and 22 (30%) patients were non-adherent 
(VERITAS-Pro≥57) (Figure 1).  At the univariate level, only age was statistically significantly related to 
non-adherence to prophylactic treatment regimens, with young adults (aged 18-25 years) having a 
higher percentage of non-adherence compared to adolescents (aged 13-17 years) (47% vs 17%, 
p=.01) (Table 1) and significantly higher (worse) median VERITAS-Pro scores (54.5 vs 45.0, p=.01) 
(Table 2).  Final logistic regression modeling (Table 3) suggested that, compared to those aged 13-17 
years, participants aged 18-25 years were 6.2 (95%CI: 1.8, 21.0; p<.01) times more likely to be non-
adherent to prescribed prophylactic treatment regimens.  The model also revealed that, compared to 
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3.8 (95%CI: 1.0, 14.3; p=.05) times more likely to be non-adherent to prophylaxis.  The final 
parsimonious model also included disease severity, race, and ethnicity because they increased the 
overall precision of the model. 
 
Discussion  
Previous studies suggest that as PWH age out of childhood and into adolescence and young 
adulthood, AYAs often begin taking primary responsibility for their bleeding disorder treatment [13, 25].  
Subsequently, adherence to prophylaxis regimens frequently worsens [17, 26] as the need for 
prophylaxis is often deprioritized or perceived as unimportant [13].  Further, as children transition into 
young adulthood, their activity level often intensifies, which could heighten the risk of bleeding.   
Results from our study support this theory, but provide even more granularity for this picture—
showing that the period of transition from adolescence into young adulthood is a critical time period 
regarding adherence to prophylaxis.  Specifically, although only 17% of participants aged 13-17 years 
(adolescents) were non-adherent to their prescribed treatment regimens, that proportion nearly tripled 
to 47% among those aged 18-25 years (young adults).  This difference persisted even after controlling 
for clinical and sociodemographic variables with logistic regression analysis showing that compared to 
adolescents, young adults were >6 times more likely to be non-adherent to prescribed prophylactic 
treatment regimens.  Reasons behind this are likely complex.  Transitioning from adolescence to young 
adulthood represents a tectonic shift as choices and challenges evolve to include decisions about 
education or career training, entering the workforce, leaving the family home, managing finances, and 
(sometimes) entering into marriage and parenthood.  All of these competing demands—compounded 
by the fact that, during young adulthood, primary responsibility for bleeding disorder care shifts from the 
parents to the patient—likely explain much of the difference in adherence to recommended prophylactic 
treatment regimens between adolescent PWH and young adult PWH that we observed.  Indeed, 
previous research suggests that as many as two-thirds of young adults will experiment with stopping or 
reducing prophylactic dosing [27].  Subsequently, the case for personalized prophylactic treatment 
plans for young (and older) adults is gaining momentum [28], and this study underscores the fact that 
among PWH, targeting the transition period from adolescence to young adulthood is important for 
maintaining adequate haemophilia treatment across the lifecourse.  Finally, it may also be that case 
that transitioning into young adulthood means leaving the health insurance coverage once provided by 
one’s parents and having to obtain health insurance coverage independently.  While health insurance 
status/type did not ultimately predict adherence in our study after, young adults (vs adolescents) (34% 
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coverage, and were more likely to rely upon public/government health insurance (e.g., Medicaid) or be 
uninsured.  Future studies should continue to evaluate the impact of health insurance status among 
young adults who are managing a bleeding disorder.       
A second finding from this study was that prophylactic adherence was worse for AYAs whose 
mothers have less formal education.  Specifically, compared to respondents whose mother had at least 
a Bachelor’s degree, respondents whose mother did not were nearly 4 times more likely to be non-
adherent to prescribed prophylactic treatment regimens.  This finding is novel and supports previous 
research that suggests better knowledge about one’s bleeding disorder and the importance of 
treatment is related to improved adherence [12, 13, 16, 18].  This finding also suggests that health care 
providers should dedicate adequate time and resources to family adherence education, and that, 
especially for AYAs, adherence efforts go beyond the patient and extend to family members and other 
social support members. 
Previous work about increasing adherence among AYA PWH has suggested that effective 
strategies might also include designing individualized prophylactic treatment regimens around “risk 
periods” (e.g., sporting events and other physical activity or time away from home), focusing on 
“wellness” instead of “adherence” per se, and recognizing health as a “state of doing” and not a “state 
of being” thereby integrating the bleeding disorder into everyday life instead of allowing the disease to 
become a burden [29].  Other research has suggested that it is important for PWH to alter the treatment 
paradigm from a victimized state where the infusion is something you do to yourself, to an 
empowerment state where the infusion is something you do for yourself [30].  These approaches, which 
stemmed from research in AYA PWH, are similar to earlier research in other (non-haemophilia) AYA 
chronic disease states that suggest motivation, a sense of normality, experience of results, and 
parental support and encouragement all lead to increased compliance [31]. 
This study has limitations.  Primarily, data are cross-sectional, thus causal inference cannot be 
made.  For example, although study results support that AYA PWH whose mothers have less formal 
education tend to have worse adherence, the directionality of this relationship cannot be confirmed.   
That is, it is also possible that AYAs who maintain adherence to prophylaxis need less medical 
attention, thereby providing a better climate for their parents to pursue college education.  This cannot 
be teased out in a cross-sectional study and should be examined in the future with prospective 
research.  A second limitation is that all data are self-reported.  As such, information about blood 
disorder type and severity, health insurance coverage, and other demographic, clinical, and behavioral 
information are not confirmed by medical record review or administrative claims data.  However, by 
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report outcomes (PRO) data about adherence.  Finally, AYA PWH were primarily recruited from large 
national or regional haemophilia meetings.  Thus, our convenience sample of AYA PWH may not 
adequately represent the broader AYA PWH population who do not typically attend these meetings.  
Despite these limitations, this is the first study to our knowledge to analyze predictors of adherence to 
prescribed prophylactic clotting-factor treatment regimens among AYAs using a standardized and 
validated patient-reported measure of adherence. 
 
Conclusion  
Previous research suggests that among AYAs with a bleeding disorder, better adherence to 
clotting-factor treatment regimens is associated with less chronic pain and the preservation of joint 
health and quality of life [3, 8-11].  Results from this study suggest that adherence efforts should be 
especially targeted to young adults as they transition from adolescence (i.e., parental supervision) and 
assume primary responsibility for their bleeding disorder care.  Finally, healthcare providers should be 
especially mindful of AYAs whose mothers have less formal education and ensure that adequate time 
and resources are dedicated to family adherence education. 
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Table 1 Respondent Characteristics by Level of Adherence as Measured by the VERITAS-Pro,  














Age   .01 
  13-17 34 (67) 7 (32) 41 (56)  
  18-25 17 (33) 15 (68) 32 (44)  
Gender     .30 
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  Female 0 (0) 1 (5) 1 (1)  
Race    .36 
  White (only) 38 (75) 19 (86) 57 (78)  
  Non-White
b
13 (25)   3 (14) 16 (22)  
Ethnicity      .26 
  Hispanic 8 (16) 1 (5) 9 (12)  
  Non-Hispanic 43 (84) 21 (95) 64 (88)  
Health Insurance  c   .30 
  Private / Commercial only 28 (55) 8 (36) 36 (49)  
  Public / Government only 12 (24) 
d
 6 (27) 18 (25)  
  Both Public and Private 2 (4) 4 (18) 6 (8)  
  Insured – type unknown 5 (10) 3 (14) 8 (11)  
  Uninsured 2 (4) 1 (5) 3 (4)  
Mother’s Education     .19 
   Bachelor’s or higher 20 (39) 5 (23) 25 (34)  
   Less than Bachelor’s 31 (61) 17 (77) 48 (66)  
Father’s Education     .99 
   Bachelor’s or higher 18 (35) 8 (36) 26 (36)  
   Less than Bachelor’s 33 (65) 14 (64) 47 (64)  
Bleeding Disorder     .53 
   Haemophilia A 46 (90) 18 (82) 64 (88)  
   Haemophilia B 3 (6) 3 (14) 6 (8)  
   von Willebrand 2 (4) 1 (5) 3 (4)  
Severity     .55 
   Mild 1 (2) 0 (0) 1 (1)  
   Moderate 3 (6) 3 (14) 6 (9)  
   Severe 45 (92) 18 (86) 63 (90)  
Inhibitor Development     .61 
   Ever 23 (45) 8 (36) 31 (42)  
   Never 28 (55) 14 (64) 42 (58)  
 
a
Adherence was assessed using the Validated Haemophilia Regimen Treatment Adherence Scale for prophylactic participants 
(VERITAS-Pro).  The cutoff for non-adherent prophylactic patients was a total VERITAS-Pro score ≥57 as established in 
Duncan N, Kronenberger W, Roberson C, Shapiro A. VERITAS-Pro: a new measure of adherence to prophylactic regimens in 
haemophilia. Haemophilia. Mar 2010;16(2):247-255.   
b
Most (13/16, 81%) of non-white respondents were black or African American, 2/16 (13%) were Asian, and 1/16 (6%) was 
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c
n=71, two respondents answered ‘Don’t Know’ to whether or not they had health insurance and were not included. 
d
Figure 1 Percentage Distribution of VERITAS-Pro Scores, 2012 (n=73)  
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The red line represents the cutoff for non-adherent prophylactic patients (VERITAS-Pro ≥57) as established by Duncan et al. 
[23].  Median VERITAS-Pro score was 48 (range=25─78) and 22 (30%) patients were non-adherent (VERITAS-Pro≥57; to the 





Table 2 VERITAS-Pro Scores by Subscale and Age Group (n=73) 
 
VERITAS-Pro Section  Median  IQR Mean Range SD 
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   Total scale 48 41─58 49.5 25─78  13.4 
   Time 8 6─11  8.9 4─20  3.9 
   Dose 4 4─8  6.1 4─15 2.8 
   Plan 6 4─9  6.8 4─16 3.0 
   Remember 9 6─12  9.1 4─18 3.7 
   Skip 7 5─10  7.7 4─16 3.4 
   Communicate 10 7─14  10.8 4─20 4.4 
Adolescents (13-17) (n=41)      
   Total scale 45 38─54 45.4 25─76  12.7 
   Time 8 5─10  8.0 4─20  4.0 
   Dose 4 4─7  5.7 4─12 2.4 
   Plan 5 4─8  6.3 4─16 2.9 
   Remember 8 5─10  8.1 4─16 3.5 
   Skip 7 4─9  7.0 4─16 3.1 
   Communicate 10 7─14  10.2 4─20 4.1 
Young Adults (18-25) (n=32)      
   Total scale 54.5 44.5─64.5 54.6 35─78  12.7 
   Time 10 8─12  10.1 4─20  3.5 
   Dose 5.5 4─9  6.8 4─15 3.2 
   Plan 7.5 4.5─9  7.5 4─16 3.1 
   Remember 11 8─12  10.3 4─18 3.5 
   Skip 8 5.5─11  8.5 4─16 3.6 
   Communicate 11.5 7.5─16  11.5 4─19 4.7 
 
Possible subscale scores ranged from four points (most adherent) to 20 (least adherent), and possible total scores ranged 
from 24 (most adherent) to 120 (least adherent).   
Table 3 Odds Ratios (OR) and 95% Confidence Intervals (CI) of Being Non-Adherent  
   as Measured by the VERITAS-Pro, 2012 (n=73)a,b 
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Age    
  18-25 6.16 (1.81, 21.0) <.01 
  13-17 1.00  
Mother’s Education    
   Less than Bachelor’s 3.77 (1.00, 14.3) .05 
   Bachelor’s or higher 1.00  
 
a
Adherence was assessed using the Validated Haemophilia Regimen Treatment Adherence Scale for prophylactic participants 
(VERITAS-Pro).  The cutoff for non-adherent prophylactic patients was a total VERITAS-Pro score ≥57 as established in 
Duncan N, Kronenberger W, Roberson C, Shapiro A. VERITAS-Pro: a new measure of adherence to prophylactic regimens in 
haemophilia. Haemophilia. Mar 2010;16(2):247-255.   
b
The model was also adjusted for disease severity and race/ethnicity.  
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